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Abstract
People with Type 2 diabetes mellitus (T2DM) have a 2–3 times higher 
cardiovascular risk (CVR) than people without diabetes. Atherosclerotic 
cardiovascular disease (ASCVD) is the major cause of morbidity and mortality in 
T2DM. Over 30% of those with T2DM have CVD (cardiovascular disease), and over 
half die from it, mainly from coronary heart disease. The presence of T2DM reduces 
life expectancy by 10–14 years. The European Society of Cardiology stratifies the 
CVR into moderate (young patients, with a short duration of diabetes, no risk 
factors), high (duration of diabetes >10 years, no target organ damage, plus any 
additional risk factor) and very high (patients with established CVD, target organ 
injury three CVD risk factors: age, hypertension, dyslipidemia, obesity, or Type 
1 diabetes mellitus (T1DM) over 20 years duration). The American Association 
of Clinical Endocrinologists (AACE) considers that diabetes per se involves high 
risk. Heart failure (HF) is the second most common complication after obstructive 
peripheral arterial disease. T2DM associates a 75% higher risk of CV mortality 
or hospitalization for HF. A multifactorial approach is required to reduce CV 
morbidity and mortality.
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1. Introduction
Diabetes mellitus (DM), a very complex and heterogeneous chronic 
disease, is associated with chronic complications generated by alteration of 
the endothelium at all arterial vascular territory levels. The micro-and macro-
vascular complications affect the entire body; their pathogenic mechanisms 
are intricate and involve multiple pathways and risk factors. The main risk 
factors are insulin resistance/hyperinsulinemia, hyperglycemia, dyslipidemia, 
hypercholesterolemia, hypertension, smoking, obesity/overweight, all of which 
cause endothelial dysfunction. Consequently, they appear vasoconstriction, 
oxidative stress, subclinical inflammation, vascular calcification and thrombosis, 
essential pathogenic elements in the process of atherogenesis/macroangiopathy and 
microangiopathy [1].
Cardiovascular disease is considered a major cause of morbidity and mortality 
among people with diabetes, with a significantly increased prevalence compare 
with people without diabetes. The risk increases with the level of glycaemia, the 
duration of diabetes and the number of risk factors. People with T2DM have much 
earlier and more extensive process of accelerated atherosclerosis, more vulnerable 
and larger volume atherosclerotic plaques and coronary artery lumen with a smaller 
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diameter, compared to people without DM. The pathogenic complex is influenced 
by genetic factors, age, personal history and a pro-risk lifestyle (unhealthy 
eating, sedentary lifestyle, smoking, sleep disorders, psychosocial stress and 
depression) [1].
The macrovascular complications mainly refer to the atherosclerotic 
cardiovascular disease, represented by coronary artery disease (acute and chronic 
coronary syndrome) (CAD), chronic peripheral artery disease (PAD) and 
cerebrovascular disease (CBV). A particular complication is heart failure (HF). The 
pathogenic mechanisms of micro-and macro-angiopathy are extremely complex, 
with multiple interactions at the molecular-cellular and vascular-organic level.
Although all complications declined in the last decades, the most significant 
decreases in diabetes-related complications occurred for heart attack and stroke, 
especially for people aged 75 years and older. The CVD risk and mortality rate 
has declined in both the general population [2] and the people with diabetes [3]. 
However, diabetes, mainly T2DM, continues to be an important generator of 
cardiovascular disease. As the number of patients with diabetes is predicted to 
increase, reaching 700 million in 2045 [4], it is expected that the number of people 
with CVD will also increase. Thus, these major diabetes complications continue to 
place a heavy burden on health care systems.
2. Cardiovascular risk
2.1 Cardiovascular risk factors in diabetes
The concept of cardiovascular risk began to be of interest in the 1930s. Studies 
of cardiovascular disease epidemiology and its causes began in the 1950s, with 
Framingham Heart Study being one of the first. This extended program has 
demonstrated the existence of multiple CVR factors over the years, introducing 
in the literature and medical concept the term “risk factor”. Among the study’s 
first results, high blood pressure, hypercholesterolemia, and smoking are 
considered traditional, classic, risk factors. Subsequently, Framingham study 
and other epidemiological studies, have identified other risk factors, including 
obesity, diabetes, dyslipidemia, sedentary lifestyle. Thus diabetes is associated 
with a 2- to 3-fold increase in the risk of developing CVD and glucose intolerance 
with a 1.5-fold increase [5–7]. In addition to hyperglycemia, diabetes, mainly 
T2DM, is accompanied by other cardiovascular risk factors, within the metabolic 
syndrome: insulin resistance, abdominal obesity, atherogenic dyslipidemia 
(hypertriglyceridemia, low HDL-C (High-density lipoprotein cholesterol), LDL-C 
(low density lipoprotein cholesterol particles), remnant lipoproteins, postprandial 
hyperlipidemia), high blood pressure, prothrombotic, proinflammatory and 
oxidative stress state, microalbuminuria, non-alcoholic fatty liver disease [8].
High blood pressure increases 2–4 times the risk of CVD, kidney and death, 
atherogenic dyslipidemia induces a residual CVR, even under statin treatment and 
LDL-C control and abdominal obesity, as a component of metabolic syndrome, 
significantly increases the risk of coronary heart disease, stroke and death [9–11].
2.2 Cardiovascular risk in T2DM
Overall, people with T2DM have 2 to 4 times increased risk of cardiovascular 
morbidity and mortality than individuals without diabetes. This risk increases with 
the increase of fasting glycaemia since the stages of prediabetes. The risk for CAD 
is rising by 160%, for ischemic heart disease by 127%, for stroke by 56%, for CVD 
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death by 132% [4], and for HF is 2–4 times higher in men and five times higher in 
women, compared to those without diabetes [5].
Epidemiological studies have revealed that the excess relative risk of vascular 
events is more significant in women, at younger ages, in long-standing DM 
and in the presence of microvascular complications, mainly renal disease or 
proteinuria [12].
Although T2DM was initially considered a “cardiovascular risk equivalent” 
[12–14], it has since been shown that CVR, mainly CAD risk, is not similar for 
all persons with diabetes, but is highly heterogeneous. Thus, the CVR should be 
differentiated based on the presence of other CVR factors or overt CVD.
For T1DM, The Swedish National Diabetes Register has shown actual results in 
CVD and CV death prevalence. [13] For T1DM, 27,195 patients were stratified by 
age and sex. Early-onset at 1–10 years of age was correlated with an HR (hazard 
ratio) of 7.38 for CV mortality, 30.95 for acute myocardial infarction (MI), and 12.9 
for heart failure (HF). Progress of T1DM between 1 and 10 years of age resulted in 
a loss of 17.7 years of life in women and 14.2 years in men. [13] Notwithstanding, 
T2DM is more common than T1DM.These results confirm the loss of years of life in 
both populations, which is more severe in the younger patients and in young-onset 
female individuals with T2DM, highlighting the need for early and intensive risk-
factor interventions in these clusters of patients. [12]
The European Society of Cardiology stratifies the CVR into three risk categories, 
including T1DM, considering that presence of DM overall represents a significant 
risk factor for CVD:
• moderate: young patients (T1DM aged <35 years or T2DM aged <50 years), 
with DM duration <10 years, without other risk factors,
• high: patients with DM duration ≥10 years without target organ damage plus 
any other additional risk factor, and
• very high: patients with DM and established CVD, or further target organ 
damage (proteinuria, renal impairment defined as eGFR <30 mL/min/1.73 m2, 
left ventricular hypertrophy, or retinopathy), or three or more major risk 
factors (age, hypertension, dyslipidemia, smoking, obesity), or early-onset 
T1DM of >20-year duration [12].
The American Association of Clinical Endocrinologists (AACE) stratifies the 
CVR into three levels: high (DM without other CVR factors), very high (DM with 
at least one CVR factor), and extreme risk (overt CVD in those with DM, chronic 
kidney disease) [15].
T2DM is reputed as an independent risk factor for the development of HF. 
Higher levels of glycated hemoglobin A1c (HbA1c) in T2DM patients have been 
associated with significantly more incident HF cases than in patients with T2DM 
and lower HbA1c levels. The incidence is even higher in patients with established 
CAD, in which each 1% increase in HbA1c level was associated with a 36% increased 
risk for HF hospitalization [16].
2.3 Cardiovascular risk assessment
A rational and successful approach to reducing the CVR involves stratifying 
risk and the periodic evaluation of the outcomes. Accurate CVD risk estimation 
in people with T2DM without established CVD can identify patients at high risk 
of developing CVD and can thus be used to adapt the intensity and complexity of 
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appropriate treatment. For practice, CVR assessment scores which can be applied in 
diabetes are beneficial. Several CVR calculation scores in DM have been developed. 
The first is the result of the United Kingdom Prospective Diabetes Study (UKPDS), 
in which, in people newly diagnosed with T2DM, the effect of intensive treatment 
on the evolution of chronic complications compared to conventional treatment was 
followed. UKPDS Risk Engine estimates the risk of fatal and non-fatal coronary 
events and fatal and non-fatal stroke at 15 and 30 years, in people with T2DM 
without CV disease, considering the duration of DM, age, gender, ethnicity, 
smoking, presence of atrial fibrillation, the level of HbA1c, systolic blood pressure, 
total cholesterol and HDL-C (https://www.dtu.ox.ac.uk/riskengine/) [17].
Another score (Advance Risk Engine) is based on ADVANCE and 
ADVANCE-ON studies. It refers to patients with T2DM without CVD, is based on 
the usual parameters and estimates the risk of major CV events at four years, the 
risk of renal events at five years and the risk of major vascular disease at ten years 
(www.advanceriskengine.com) [18].
The American Heart Association (AHA) and American College of Cardiology 
(ACC), developed a risk score to estimate the ten-year risk for the first ASCVD 
event (non-fatal myocardial infarction or CHD death, or fatal/non-fatal stroke) 
(available online at tools.acc.org/ASCVD-Risk-Estimator-Plus) [19].
Based on the ACCORD trial population, the BRAVO risk engine has been 
recently developed. It contains three separate modules addressed to events (stroke, 
MI, HF, angina, revascularization surgery, renal events, blindness, hypoglycemia), 
risk factors and mortality [20].
None of these CVR estimation scores is perfect, so clinical judgment and 
consideration of CVR factors are important for setting and selecting appropriate 
therapeutic goals and interventions.
3. Cardiovascular disease
The high impact that T2DM has on the CVD has generated numerous studies, 
and population analyzes in order to determine the prevalence of the cardiovascular 
pathologies in people with diabetes. Although the description and the diagnostic 
criteria used to define the different manifestations of CVD were different across 
the epidemiologic studies, overall, the results show that CVD is a major cause of 
comorbidity and mortality among patients with T2DM. Thus, the CVD, including 
myocardial infarction, stroke, angina, heart failure, atherosclerosis and coronary 
artery disease, is present in 32.2% of people with T2DM. The most frequent type of 
CVD seems to be the CAD (21.2%), males having higher rates (18.7%) than females 
(14.3%) [21]. A large cohort of 1,921,260 individuals, 1.8% with T2DM, followed 
5.5 years, has been analyzed in terms of the most common initial manifestations of 
CVD. In T2DM individuals, peripheral artery disease was the most frequent first 
presentation (16.2%) followed by HF (14.1%), significantly higher compared with 
those without diabetes [22]. The prevalence of CVD and the incidence of primary 
adverse outcomes is higher in women with T2DM than their male counterparts 
(RR = 9.29; P < 0.0001 for CVD and RR = 5.25; P < 0.0001 for incident major 
adverse outcomes [23]. Data from the UK Biobank showed that a cardiovascular 
event’s excess risk was approximately 50% higher in women (HR = 1.96) than in 
men, and more importantly, the incidence of myocardial infarction (MI) [A1] 
was higher in men than in women(28.8%). This observation was exciting since the 
sex differences were the same in all age-related groups and were attenuated with 
increasing age, from 0.27 (0.18 to 0.41), in 45 years age cluster versus 0.45 (0.40 to 
0.50) in 65 years age cluster. [24].
5
Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus
DOI: http://dx.doi.org/10.5772/intechopen.97422
Although diabetes-related excess mortality is lower in the contemporary era 
than previously, T2DM is associated with a two to six times increased risk of CVD 
mortality than people without diabetes. Cardiovascular disease accounts for 52% 
of deaths in type 2 DM [25]. MI is considered to be the main cause of death for 
individuals with diabetes mellitus.
T2DM is a significant predictor of HF, independent of the simultaneous 
presence of hypertension and coronary heart disease. In diabetes, HF has multiple 
risk factors: hyperglycemia, insulin resistance, age, ischemic heart disease, high 
blood pressure, left ventricular hypertrophy, diffuse, accelerated and severe 
atherosclerosis. Even in the absence of CAD, microvascular complications, arterial 
thickening and fibrosis, endothelial and vasomotor dysfunction, increase the risk 
of HF. The risk of HF is 2–4 times higher in men and five times higher in women 
compared to those without diabetes, according to Framingham Heart Study [5, 16].
The presence of DM in those hospitalized for HF worsens the prognosis, 
prolongs hospitalization, and increases the number of hospitalizations and 
the risk of death. In stable forms of HF, T2DM is an independent predictor of 
hospitalization and mortality, regardless of the ejection fraction [26]. Patients with 
T2DM have a 2.5-fold increased risk of developing HF and a 75% higher risk of CV 
mortality or hospitalization for HF than those without DM [27].
HF with preserved ejection fraction (HFpEF) is a frequent phenotype in T2DM 
and is related to an important risk of morbidity and mortality than those without 
diabetes, with multiple comorbidities, reduced exercise capacity, increased markers 
of inflammation, fibrosis, endothelial dysfunction, congestion, increased left 
ventricular pressure [28].
At similar ejection fraction values, patients with T2DM have a higher NYHA 
functional class, and more expressed symptoms than those without diabetes. Left 
ventricular (LV) diastolic dysfunction can be detected in approximately 75% of 
patients with T2DM, even in the early stages. The degree of hyperglycemia and its 
duration correlate with LV diastolic dysfunction’s severity, with the increased risk of 
HF and CV mortality [16].
A retrospective cohort study that included 208,792 adults with diabetes has 
analyzed the impact of varying combinations of heart disease, stroke, moderate 
chronic kidney disease (CKD) on mortality, over a median follow-up of 8.5 years 
[29]. The effect of heart diseases, stroke, CKD, and the combination of these 
conditions on all-cause mortality has been found to be independent and cumulative. 
The mortality risks were 1.75 times, 2.63 times, and 3.58 times greater for patients 
with one, two, and all three above mentioned conditions, and life expectancy for 
a 40-year-old with one, two, and three conditions was reduced with 20, 25, and 
30 years for men and 25, 30, and 35 years, respectively, for women, compared with 
patients without these diseases [29].
Diabetes is the most known cause of CKD, and end-stage renal disease, more than 
50% of people with DM are likely to develop CKD. CKD, especially severe CKD, has a 
significant impact on life expectancy and mortality risk in patients with diabetes. The 
risk of CV death increases as renal function declines (eGFR <60 ml/min/1.73 m2 and/or 
ACR (albumin-creatinine ratio) ≥10 mg/g) [30]. Rates of HF are approximately 3-times 
higher in patients with eGFR <60 ml/min/1.7 m2 [31].
The CardioRenal Metabolic Syndrome (CaReMe) has been introduced as 
terminology to describe the ongoing relationship between obesity, diabetes, 
kidney disease and heart failure with preserved systolic function, with significant 
mortality implications rate and therapeutic interventions [32].
Within CVD, diabetic cardiomyopathy or “cardiac microvascular disease”, 
is a phenotype with distinct manifestations, described as a “structural and 
functional alteration of the myocardium, in the absence of hypertension, ischemic 
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coronary heart disease, valvulopathies, or other FRCV, in patients with diabetes, 
especially with long-term diabetes and poor control.” Fibrosis, stiffness, and 
cardiac hypertrophy are basic changes, which are initially associated with diastolic 
dysfunction, LV hypertrophy and reduced compliance with preserving the ejection 
fraction, later evolving into systolic dysfunction clinically manifest HF [16, 33]. 
As risk factors of diabetic cardiomyopathy, hyperglycemia, dyslipidemia, altered 
energy metabolism, dysregulated insulin signaling, inflammation, endoplasmic 
reticular stress, mitochondrial dysfunction, oxidative stress and accumulation of 
advanced glycation end-products (AGEs) and activation of the renin-angiotensin-
aldosterone system (RAAS) are described [33].
4. Hyperglycemia and CVD relationship
Compared with individuals without diabetes, patients with T2DM are 
disproportionately affected by CVD morbidity and mortality. Most of this excess 
risk is associated with an increased prevalence of risk factors such as hypertension, 
dyslipidemia, and obesity in these patients. However, hyperglycemia, as a distinct 
characteristic of DM, appears to be an independent risk factor for all-cause and 
CVD mortality independent of other modifiable CVD risk factors:
• Increased HbA1c is associated with coronary heart disease [34],
• Long-term intraindividual variability of HbA1c or basal blood glucose 
is associated with micro-and macro-vascular complications and with an 
increased risk of important adverse CV events [35–37],
• 24-hour glycemic variability, greater than 35.9 mg/dl, is independently 
associated with an increased risk of left ventricular diastolic dysfunction, even 
in asymptomatic patients and with a preserved ejection fraction (odds ratio: 
3.67; p < 0.05) [38],
• Basal glycemia >126 mg/dl was associated with a risk of fatal/non-fatal coronary 
heart disease, fatal/non-fatal stroke of 39% in women and 48% in men [39],
• Each 1-point increase in HbA1c is associated with an 8% increase in the risk of 
HF and a 36% increased risk for HF hospitalization [16, 39],
• The onset of diabetes in young people and the long duration of diabetes, are 
associated with an increased risk of mortality, mainly CV, due to ischemic 
disease and stroke [40, 41],
• The risk of coronary artery disease increases in diabetic patients by 11% for 
each 1% increment in HbA1c greater than 6.5%. In adults with diabetes, but 
without baseline CVD, an HbA1c of 9% is correlated with an increased risk of 
myocardial infarction or acute coronary syndrome (odds ratio [OR] = 1.18), 
stroke (OR = 1.29) and heart failure (OR = 1.37) [42],
• Severe hypoglycemia is linked with an increased risk of recurrence (especially 
in T1DM) and an increased risk of CV events, including death. In the Veteran 
Affairs Diabetes Trial, severe hypoglycemia was associated in the following 
3 months with CV events (HR = 1.9; p = 0.03), CV mortality (HR = 3.7; 
p = 0.01) and mortality of any cause (HR = 2.4; p = 0.02) [43].
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5. Therapeutic approach
The major objectives of clinical management in T2DM are preventing or 
delaying chronic complications, increasing life expectancy, and quality. The basic 
principle of clinical management is the “patient-centred” approach, respectively, 
the intervention’s individualisation [19]. The significant reduction of cardiovascular 
morbidity/mortality implies a multifactorial approach, addressed simultaneously 
to all CV risk factors. The 7.8-year STENO-2 study, which included patients with 
T2DM with increased CV risk (microalbuminuria), showed that the multifactorial 
approach significantly reduced mortality from any cause (20% reduction in 
absolute risk), 13% in CV mortality and 29% in the absolute risk of CV events 
[44, 45]. The 21-year assessment showed that life expectancy was extended by 
eight years in the intensive care group, and the relative risk of HF was reduced by 
76% [45]. Analysis of data from an extensive registry has shown that in people 
with T2DM, simultaneous control of major CV risk factors (blood glucose, 
blood pressure, cholesterol and lifestyle, no smoking), can reduce over 60% of 
cardiovascular and coronary atherosclerotic events [46]. Patients with diabetes who 
have five risk-factor variables within the target ranges (HbA1c, LDL-cholesterol, 
blood pressure, no albuminuria and no smoking) seem to have lower or no excess 
risk of overall death or myocardial infarction and/or stroke, as similar to the 
general population, as shown in a study that included 271,174 patients with T2DM 
registered in the Swedish National Diabetes Register [47].
5.1 Specific therapeutic targets
The specific targets of clinical management are presented in Table 1.
5.2 Lifestyle optimization
Lifestyle interventions addressed to optimize nutrition, increase physical 
activity, control body weight, stop smoking, are the cornerstone for T2DM therapy, 
for both glycemic and other CV risk factors [19, 50]. In terms of CV risk control, 
lifestyle management aims to, and it is proven to achieve [51]:
• Control of body weight and improvements of obesity-related complications,
• Improvement of glycemic control,
• Lowering of blood pressure,
• Improvement of the lipid profile
• Improvement of fitness, well-being and mental health.
Although the Look AHEAD (Action for Health in Diabetes) study did not show.
that intensive lifestyle optimization reduces CV events in people with diabetes 
and obesity, it showed significant control of CV risk factors, with fewer medication 
requirements and long-term weight loss maintenance (4.7% at eight years) [52].
5.2.1 Medical nutrition therapy
Medical nutrition therapy is based on healthy eating principles. Its goals are to 
promote and support healthful eating patterns, with various nutrient-dense foods 
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in appropriate portion sizes. To ensure adherence and effectiveness, nutritional 
interventions should be individualized by meeting individual’s needs, personal and 
cultural preferences, access to healthy foods, the pleasure of eating, and providing 
practical tools to implement the recommendations [50].
Dietary interventions can reduce HbA1c with up to 2% [50]. Caloric intake 
should be adapted to maintain body weight control. General recommendations are to 
avoid saturated lipids and foods with a high glycemic index. The Mediterranean diet, 
the DASH diet (Dietary Approaches to Stop Hypertension), plant-based diets, are 
recommended for their proven benefits. Carbohydrates should come from foods rich 
in fibers: vegetables, legumes, whole grains, fruits. Lipids should be mainly mono- 
and polyunsaturated and omega-3. Supplementation with minerals or vitamins is 
only recommended in case of deficiency. Hydration is important, with the selection 
of non-caloric drinks. Consumption of alcohol in moderate amounts is acceptable, 
but special attention should be paid to the risk of hypoglycemia, hyperglycemia and 
additional caloric intake. Sodium intake should be <2,300 mg/day [50].
Risk factors Therapeutic targets
HbA1c [19] < 7% (53 mmol/mol), for most patients
< 6,5% (48 mmol/mol), if the target can be achieved without hypoglycemia† 
(usually younger patients, short duration of diabetes, longer life expectancy, no 
complications)
< 8% (64 mmol/mol), for patients with long-standing diabetes, complex 
glucose-lowering treatment including insulin, history of severe hypoglycemia, 







• Postprandial glycemia (1–2 hours) < 180 mg/dl
• Reduced glycemic variability (< 36%)
• Avoidance of hypoglycemia:
> 70% time in range (70–180 mg/dL/3.9–10.0 mmol/L)
< 4% glucose range below 70 mg (3.9 mmol/L)
Blood pressure [18, 19] < 130/80 mmHg (≥ 65 years = 130–139/70–79 mmHg)
Lipids [12] • LDL-cholesterol:
< 100 mg/dl - moderate CV risk
< 70 mg/dl and > 50% reduction - high CV risk
< 55 mg/dl and > 50% reduction – very high CV risk
• Non-HDL-col <85 mg/dl in patients at very high CVR, and < 100 mg/dl in 
those at high CVR
• HDL-cholesterol >40 mg/dl in men and > 45 mg/dl in women *
• Triglycerides <150 mg/dl *
Body weight [19] > 5–10% weight loss and
• long term weight loss maintenance
Lifestyle [19] • Physical activity
• Healthy nutrition, caloric adjusted
• No smoking
• No/moderate alcohol intake
†Glucose range below 70 mg/dl in less then 4% of the measurements determined by continuous glucose monitoring or 
ambulatory glycemic profile per day [19, 49].
*Not a goal but indicates a lower risk.
Table 1. 
Therapeutic targets in T2DM (adapted by [12, 19, 48, 49]).
9
Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus
DOI: http://dx.doi.org/10.5772/intechopen.97422
5.2.2 Physical activity
Most patients’ recommended physical activity is at least 150 minutes/week, 
at least three times/week, moderate/high intensity, aerobic, 2–3 sessions/week of 
endurance and flexibility exercises. Reducing the time spent in sedentary lifestyle is 
also an important recommendation [50].
5.3 Pharmacotherapy
5.3.1 Pharmacotherapy of hyperglycemia
The pharmacotherapy of hyperglycemia should be patient-centred, addressed 
to reduce glycemia and the overall CVR [53]. Metformin remains the first step of 
the treatment. It is initiated simultaneously with lifestyle optimization, from the 
diagnosis, and is continued throughout the treatment, associated with the other 
therapeutic classes. It is stopped in case of intolerance and at an eGFR <30 mL/
min/1.73 m2. For patients with established ASCVD or indicators of high ASCVD 
risk, established kidney disease, or heart failure, the guidelines recommend the 
medication with demonstrated CVD benefit, independent of the HbA1c value: 
SGLT-2 inhibitor (sodium-glucose cotransporter 2 inhibitor – empagliflozin, 
canagliflozin, dapagliflozin) or GLP-1RA (glucagon-like peptide 1 receptor ago-
nist – semaglutide, liraglutide, dulaglutide, long-acting exenatide, lixisenatide) 
(Table 2) [12, 19, 53–59].
For patients without the conditions mentioned above, a second or third agent’s 
choice as an add-on to metformin is based on CV safety, the effect on body weight, 
and avoidance of hypoglycemia. Sulfonylureas have controversial CV effects. To 
date, the ADVANCE study (Action in Diabetes and Vascular Disease: Preterax 
GLP-1 RA/Study


























































Antihyperglycemic agents with proven CVD/CKD/hHF benefits [12, 19, 53–59].
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and Diamicron MR Controlled Evaluation) is the only one that has shown that 
gliclazide is CV neutral and has beneficial effects in reducing kidney disease [60]. 
The PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular 
Events) which included patients with T2DM treated with pioglitazone in second-
ary prevention, demonstrated benefits of reducing events (myocardial infarction, 
stroke), but also increased risk for heart failure [61]. DPP-IV-inhibitors (dipeptidyl 
peptidase IV), are CV safe, body weight neutral, and with low risk for hypogly-
cemia. Insulin therapy is initiated at HbA1c values above 10%, or in the presence 
of symptoms of hyperglycemia. New generations of basal insulin analogues are 
recommended, preferably in association with GLP-1 RA [53].
Mention: only the statistically significant results are included in the table; 
HR-hazard ratio; NS-non statistically significant; MACE-major adverse cardiovas-
cular events: CV mortality, non-fatal myocardial infarction and non-fatal stroke; 
hHF- hospitalization for heart failure; Renal effects: new or worsening nephropathy 
(persistent macroalbuminuria, persistent doubling of the serum creatinine level 
and a creatinine clearance of less than 45 ml per minute per 1.73 m2 of body-surface 
area, or the need for continuous renal-replacement therapy); LEADER- Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; 
SUSTAIN-Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-
naïve Subjects With Type 2 Diabetes; EXSCEL- Exenatide Study of Cardiovascular 
Event Lowering Trial; EMPA-REG-OUTCOME-The Empagliflozin Cardiovascular 
Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess 
Glucose; CANVAS- Canagliflozin Cardiovascular Assessment Study; DECLARE-
TIMI 58-Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in 
Myocardial Infarction 58.
Unfortunately, the Exenatide Study of Cardiovascular Event Lowering 
(EXSCEL) was unable to demonstrate that once-weekly exenatide can achieve a 
statistically significant reduction in the incidence of major adverse cardiovascular 
events, compare to placebo [62].
DAPA-HF study (“Dapagliflozin and Prevention of Adverse Outcomes in 
Heart Failure”), which included patients with heart failure (ejection fraction 
<40% and NYHA class II-IV or symptoms) has demonstrated, after a median of 
18.2 months of treatment with dapagliflozin vs. placebo, a significant reduction 
(HR = 0.74) of the primary composite outcome (worsening heart failure or death 
from cardiovascular causes) and the secondary outcomes (cardiovascular death or 
heart-failure hospitalization) (HR = 0.75) [63]. A similar design has been used in 
EMPEROR-Reduced trial (Empagliflozin Outcome Trial in Patients with Chronic 
Heart Failure and a Reduced Ejection Fraction). Compare to placebo, empagliflozin 
has significantly reduced the primary composite outcome of death from 
cardiovascular causes or hospitalization for HF (HR = 0.75) and the total number of 
hospitalizations for heart failure (HR = 0.70) [64].
5.3.2 Pharmacotherapy of hypertension
At a systolic blood pressure ≥ 140 mmHg and/or diastolic blood 
pressure ≥ 90 mmHg, drug therapy is necessary in combination with non-
pharmacological treatment [12, 19]. An association of antihypertensive classes is 
often needed, with a renin-angiotensin-aldosterone system (RAAS) blocker, and a 
calcium channel blocker or diuretic. A RAAS blocker is recommended particularly 
in the presence of microalbuminuria, albuminuria, proteinuria, or LV hypertrophy. 
Dual therapy is recommended as first-line treatment, with a combination of a 
RAAS blocker with a calcium channel blocker or thiazide/thiazide-like diuretic. 
It is recommended that at least one antihypertensive drug to be administered 
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in the evening [12]. In the case of resistant hypertension, if therapeutic targets 
are not met with three classes of antihypertensive drugs (including a diuretic), 
a mineralocorticoid receptor antagonist (spironolactone) is added. Fixed 
combinations are preferred to increase adherence [12, 19].
5.3.3 Pharmacotherapy of dyslipidemia
LDL-cholesterol is the first therapeutic target. Depending on the risk class, 
statins are used in moderate doses (Atorvastatin 10–20 mg, Rosuvastatin 5–10 mg, 
Simvastatin 20–40 mg) or high doses (Atorvastatin 40–80 mg, Rosuvastatin 
20–40 mg) [12, 19, 48]. If LDL-C target is not reached, ezetimibe or PCSK9 
inhibitors (evolocumab or alirocumab) are added. In the presence of atherogenic 
dyslipidemia (persistent triglycerides >200 mg/dl), the fenofibrate can be added 
to statin. The lipid arm of ACCORD study showed a further 31% reduction in CV 
events’ relative risk in this combination. Omega-3 fatty acids can further reduce 
the level of triglycerides in a dose of >2 g/day. The “Reduction of Cardiovascular 
Events with EPA-Intervention Trial (REDUCE-IT) study”, showed that 2 grams 
icosapent ethyl (EPA), administered twice daily, was associated with 25% relative 
risk reduction (P < 0.001) in major adverse CV events (MACE), compared to 
placebo [65].
5.3.4 Antithrombotic/anticoagulant pharmacotherapy
If there is no contraindication, in individuals with T2DM over the age of 50, 
at high/very high CV risk, in the presence of the family history of premature 
atherosclerotic disease, hypertension, dyslipidemia, smoking, chronic kidney 
disease, aspirin (75–100 mg/day) may be considered in primary prevention. Aspirin 
(75–162 mg/day), or clopidogrel (75 mg/day) are recommended for secondary 
prevention. Dual antiplatelet therapy (low-dose aspirin and P2Y12 inhibitors: 
ticagrelor, clopidogrel, prasugrel) is recommended after an acute coronary 
syndrome, for a period of one year, possibly with benefits and longer use [12, 19].
Rivaroxaban 2.5 mg administered twice daily in combination with 100 mg 
aspirin, in T2DM patients with stable atherosclerotic vascular disease, has been 
shown to significantly reduce the primary outcome of CV death, stroke, myocardial 
infarction and major adverse limb events including amputation, but with more 
major bleeding events than those assigned to aspirin alone [66, 67].
5.3.5 Surgical procedures
a. Bariatric surgery is associated with the most important and sustained weight 
loss, with significant improvements in CV risk factors, including remission 
of T2DM, cardiac functional parameters and coronary events. The criteria for 
recommending bariatric surgery in people with T2DM are [68, 69]:
• BMI ≥ 40 kg/m2
• BMI = 35.0–39.9 kg/m2 if long-term weight loss and improvement of 
comorbidities by non-surgical methods could not be achieved
• BMI = 30.0–34.9 kg/m2 in certain situations [69]
b. Myocardial revascularization strategies, either percutaneous coronary inter-
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everolimus-eluting stents, or coronary artery bypass graft surgery (CABG), are 
strongly recommended in patients with T2DM. Based on the coronary anatomy 
complexity, PCI may represent an alternative to CABG for lower complexity, 
while CABG is recommended for intermediate-to-high anatomical complex-
ity [19].
6. Conclusions
T2DM is a major cardiovascular risk factor. CVD is frequent, associated with 
high mortality.
The clinical management of T2DM must be early, multifactorial, intensive, and 
patient-centred. Lifestyle intervention and a combination of several classes of drugs 
should be addressed to all cardiovascular risk factors.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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